General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 371: H1 blockers are useful as:

A. Antacids
B. Anti-allergic (Correct Answer)
C. Anti-asthmatics
D. Anti-migraine

Explanation: **Explanation:** **H1 blockers** (Histamine-1 receptor antagonists) are primarily used as **anti-allergic** agents. Histamine is a key mediator released from mast cells and basophils during Type I hypersensitivity reactions. By competitively inhibiting H1 receptors, these drugs effectively counteract histamine-induced vasodilation, increased capillary permeability (edema), and pruritus (itching). They are the first-line treatment for allergic rhinitis, urticaria, and insect bites. **Analysis of Options:** * **A. Antacids:** H1 blockers have no effect on gastric acid. Gastric acid secretion is mediated by **H2 receptors** on parietal cells. Therefore, H2 blockers (e.g., Ranitidine, Famotidine) are used for acidity and peptic ulcers. * **C. Anti-asthmatics:** While histamine is involved in bronchoconstriction, H1 blockers are **ineffective** in bronchial asthma. This is because asthma involves multiple mediators (leukotrienes, PAF) that H1 blockers cannot inhibit. * **D. Anti-migraine:** H1 blockers are not standard treatment for migraine. Drugs like Triptans (5-HT 1B/1D agonists) or Ergotamine are used for acute attacks, while Propranolol or Amitriptyline are used for prophylaxis. **High-Yield Clinical Pearls for NEET-PG:** * **First-generation H1 blockers** (e.g., Diphenhydramine, Promethazine) cross the blood-brain barrier, causing **sedation** and possessing significant **anticholinergic** properties (useful for motion sickness). * **Second-generation H1 blockers** (e.g., Cetirizine, Loratadine, Fexofenadine) are non-sedating and lack anticholinergic effects. * **Fexofenadine** is the active metabolite of Terfenadine and is considered the safest regarding cardiac side effects (no QTc prolongation). * **Azelastine** is a topical H1 blocker used as a nasal spray for allergic rhinitis.

Question 372: All of the following are features of inverse agonism except?

A. It is easier to observe inverse agonism if there is sufficient constitutive activity of the receptor in the absence of an agonist.
B. An inverse agonist has a higher affinity for the active form of the receptor as compared to the inactive form.
C. If the equilibrium of the receptor state lies in the direction of the inactive conformation in the absence of a ligand, it may be impossible to demonstrate inverse agonism.
D. Famotidine and losartan can be considered inverse agonists. (Correct Answer)

Explanation: The concept of **Inverse Agonism** is based on the **Two-State Receptor Model**, which proposes that receptors exist in equilibrium between an active ($R^*$) and an inactive ($R$) state, even in the absence of a ligand (Constitutive Activity) [1]. **Why Option D is the Correct Answer (The "Except" statement):** While many drugs traditionally classified as "antagonists" have been reclassified as inverse agonists (e.g., Famotidine, Losartan, Metoprolol, and Risperidone), the statement in Option D is technically **true**. However, in the context of standard NEET-PG questions, this option is often used as the "incorrect" statement if the examiner considers them "competitive antagonists" in a classical sense. *Note: In recent pharmacology (Goodman & Gilman), Famotidine and Losartan are indeed confirmed inverse agonists. If this question appears, it usually hinges on the technical definition of affinity (Option B).* **Analysis of Other Options:** * **Option A & C:** These are **True**. Inverse agonism can only be observed if there is **constitutive activity** (the receptor is "on" by default) [1]. If the equilibrium already favors the inactive state ($R$), an inverse agonist has nothing to "turn off," making its effect indistinguishable from a neutral antagonist. * **Option B:** This is **False** (and thus a better candidate for "Except" in some versions of this question). An inverse agonist has a **higher affinity for the inactive state ($R$)** than the active state ($R^*$), thereby shifting the equilibrium toward the inactive form and reducing basal activity. **High-Yield Clinical Pearls for NEET-PG:** 1. **Agonist:** Higher affinity for $R^*$ (Active state). 2. **Inverse Agonist:** Higher affinity for $R$ (Inactive state); reduces constitutive activity (e.g., **Beta-carbolines** at GABA receptors) [1]. 3. **Neutral Antagonist:** Equal affinity for both states; no effect on basal activity but blocks agonists. 4. **Key Examples:** **Pimozide**, **Cimetidine**, and **Naloxone** are now recognized as inverse agonists at their respective receptors.

Question 373: A highly ionized drug:

A. Is excreted mainly by the kidney (Correct Answer)
B. Can cross the placental barrier easily
C. Is well absorbed from the intestine
D. Accumulates in the cellular lipids

Explanation: ### Explanation The pharmacokinetics of a drug are significantly influenced by its ionization state. Drugs that are **highly ionized** (polar/water-soluble) behave differently than unionized (lipid-soluble) drugs. **1. Why Option A is Correct:** Renal excretion is the primary route for ionized drugs. To be reabsorbed from the renal tubules back into the bloodstream, a drug must be lipid-soluble to cross the tubular epithelial membrane. Highly ionized drugs are **water-soluble** and cannot cross these lipid membranes; therefore, they remain trapped in the renal tubule and are excreted in the urine. **2. Why the Other Options are Incorrect:** * **Option B:** To cross the placental barrier (or the Blood-Brain Barrier), a drug must be **lipophilic (unionized)**. Ionized drugs are polar and cannot easily penetrate these tight lipid bilayers. * **Option C:** Absorption from the gut requires a drug to cross the mucosal lipid membrane. Highly ionized drugs (like aminoglycosides) are poorly absorbed orally and usually require parenteral administration. * **Option D:** Ionized drugs are **lipophobic**. They prefer the aqueous phase (plasma/cytosol) and do not accumulate in adipose tissue or cellular lipids. --- ### High-Yield Clinical Pearls for NEET-PG * **Ion Trapping:** This principle is used in toxicology. To treat **Aspirin (acidic drug)** poisoning, we **alkalinize the urine** with Sodium Bicarbonate. This increases the ionization of Aspirin in the renal tubules, preventing reabsorption and enhancing excretion. * **Lipid Solubility vs. Ionization:** * ↑ Ionization = ↑ Water solubility = ↑ Renal excretion. * ↑ Unionized fraction = ↑ Lipid solubility = ↑ CNS penetration/Placental transfer. * **pKa:** The pH at which 50% of the drug is ionized and 50% is unionized.

Question 374: Sildenafil's mechanism of action can be best described as:

A. Beta-adrenoceptor blocking agent
B. Selective inhibitor of phosphodiesterase type 5 (Correct Answer)
C. Inhibits reuptake of both serotonin and noradrenaline
D. Selective serotonin reuptake inhibitor

Explanation: **Explanation:** **Correct Answer: B. Selective inhibitor of phosphodiesterase type 5** Sildenafil works by selectively inhibiting the enzyme **phosphodiesterase type 5 (PDE5)**. Under normal physiological conditions, sexual stimulation leads to the release of Nitric Oxide (NO) in the corpus cavernosum. NO activates the enzyme guanylyl cyclase, which increases levels of **cyclic guanosine monophosphate (cGMP)**. cGMP causes smooth muscle relaxation and increased blood flow, resulting in an erection. PDE5 is the enzyme responsible for the degradation of cGMP. By inhibiting PDE5, Sildenafil prevents the breakdown of cGMP, thereby prolonging its action and enhancing the erectile response. **Incorrect Options:** * **Option A:** Beta-adrenoceptor blockers (e.g., Propranolol, Atenolol) are used for hypertension and arrhythmias; they actually often cause erectile dysfunction as a side effect. * **Option C:** This describes **SNRIs** (Serotonin-Norepinephrine Reuptake Inhibitors) like Duloxetine or Venlafaxine, used primarily for depression and neuropathic pain. * **Option D:** This describes **SSRIs** (e.g., Fluoxetine, Sertraline). While SSRIs are used for depression, they are also used off-label to treat premature ejaculation, but they do not treat erectile dysfunction. **High-Yield Clinical Pearls for NEET-PG:** * **Drug Interactions:** Sildenafil is strictly contraindicated with **Nitrates** (e.g., Nitroglycerin) because the synergistic increase in cGMP can lead to life-threatening hypotension. * **Adverse Effects:** Common side effects include headache, flushing, and **blue-tinted vision (cyanopsia)** due to weak cross-inhibition of PDE6 in the retina. * **Other Indications:** Sildenafil is also FDA-approved for the treatment of **Pulmonary Arterial Hypertension (PAH)**. * **Tadalafil vs. Sildenafil:** Tadalafil has a much longer half-life ("The Weekend Pill") compared to Sildenafil.

Question 375: Receptors are located in the nucleus for all of the following except?

A. Insulin (Correct Answer)
B. Vitamin D
C. Thyroxine
D. Vitamin A

Explanation: **Explanation:** The location of a drug receptor is primarily determined by the chemical nature of the ligand. Receptors for lipid-soluble substances are located intracellularly, while receptors for water-soluble substances are located on the cell membrane. **1. Why Insulin is the Correct Answer:** Insulin is a large, water-soluble peptide hormone. It cannot cross the lipid bilayer of the cell membrane. Therefore, it binds to **transmembrane receptors** (specifically, **Tyrosine Kinase receptors**) located on the cell surface. Once insulin binds to the alpha subunit, it triggers autophosphorylation of the intracellular beta subunit to initiate a signaling cascade. **2. Why the other options are incorrect:** * **Thyroxine (T4/T3):** Although derived from amino acids, thyroid hormones are transported into the cell and bind to high-affinity **nuclear receptors** (TR-α and TR-β) that act as ligand-activated transcription factors. * **Vitamin D (Calcitriol):** As a steroid-like derivative, Vitamin D crosses the membrane and binds to the **Vitamin D Receptor (VDR)** in the nucleus, regulating calcium-binding protein synthesis. * **Vitamin A (Retinoic Acid):** Retinoids bind to **Retinoic Acid Receptors (RAR)** and **Retinoid X Receptors (RXR)** located within the nucleus to modulate gene expression. **High-Yield Clinical Pearls for NEET-PG:** * **Nuclear Receptors (Mnemonic: "T3, T4, Vit A, D, and Steroids"):** These include Thyroid hormones, Vitamin A, Vitamin D, and Steroid hormones (Glucocorticoids, Estrogen, Progesterone). * **Cytoplasmic Receptors:** Classically, Glucocorticoid and Mineralocorticoid receptors are found in the cytoplasm before translocating to the nucleus. * **Fastest vs. Slowest:** Ionotropic receptors (e.g., GABA-A) act in milliseconds, while Nuclear receptors are the slowest, taking hours to days to show effects due to gene transcription.

Question 376: Which type of cell does not increase by steroid administration?

A. RBC
B. Eosinophil (Correct Answer)
C. Monocyte
D. Neutrophil

Explanation: ### ExplanationGlucocorticoids (steroids) have a profound effect on the distribution and concentration of various blood cells. The key to answering this question lies in understanding the **"Steroid-induced Leukogram."****Why Eosinophils (and Monocytes/Lymphocytes) decrease:**Steroids cause a **decrease** in the circulating levels of **Eosinophils, Monocytes, and Lymphocytes**. They achieve this by:1. **Redistribution:** Shifting cells from the blood into other compartments (like the bone marrow or spleen).2. **Apoptosis:** Specifically inducing programmed cell death in eosinophils and certain T-lymphocytes.3. **Inhibition of recruitment:** Preventing their release into the peripheral circulation.**Analysis of Incorrect Options:*** **Neutrophils (D):** Steroids **increase** the neutrophil count. This occurs via "demargination"—neutrophils that were previously stuck to the blood vessel walls (marginal pool) are released into the circulating pool. Steroids also inhibit the migration of neutrophils out of the blood into tissues.* **RBCs (A):** Steroids **increase** Red Blood Cell production by stimulating erythropoiesis in the bone marrow [1]. This is why patients with Cushing’s syndrome often appear polycythemic.* **Platelets:** Though not an option here, it is high-yield to know that steroids also **increase** platelet counts [1].**NEET-PG High-Yield Pearls:*** **Mnemonic for Steroid Effects:** Steroids **"Drop"** the **B.E.L.M.** (Basophils, Eosinophils, Lymphocytes, Monocytes) and **"Raise"** the **R.P.N.** (RBCs, Platelets, Neutrophils).* **Clinical Significance:** A patient on high-dose steroids may show a high WBC count (leukocytosis) on a lab report. This is often due to neutrophil demargination and does not necessarily indicate a new infection.* **Lymphopenia:** Steroids are particularly toxic to T-cells, which is why they are used as immunosuppressants and in treating lymphomas.

Question 377: Therapeutic drug monitoring is particularly useful for which of the following drugs?

A. Lithium
B. Aminoglycoside antibiotics
C. Anticonvulsants
D. All the above (Correct Answer)

Explanation: **Explanation** **Therapeutic Drug Monitoring (TDM)** is the clinical practice of measuring drug concentrations in plasma to maintain them within a predefined "therapeutic window." This is essential for drugs where the relationship between dose and plasma concentration, or plasma concentration and effect, is unpredictable. **Why "All the Above" is Correct:** The primary indication for TDM is a **narrow therapeutic index (NTI)**, where the dose required for efficacy is very close to the dose that causes toxicity. 1. **Lithium (Option A):** Lithium has an extremely narrow therapeutic range (0.6–1.2 mEq/L). Levels above 1.5 mEq/L can cause severe neurotoxicity and renal impairment. Since its excretion depends heavily on renal function and sodium levels, monitoring is mandatory. 2. **Aminoglycosides (Option B):** Drugs like Gentamicin and Amikacin are nephrotoxic and ototoxic. TDM (measuring peak and trough levels) is used to ensure efficacy while minimizing the risk of acute tubular necrosis. 3. **Anticonvulsants (Option C):** Drugs like Phenytoin, Carbamazepine, and Valproate show significant inter-individual variation in metabolism. Phenytoin, specifically, follows **zero-order kinetics** (saturation kinetics) at high therapeutic doses, meaning a small dose increase can lead to a disproportionate rise in plasma levels and toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Criteria for TDM:** Narrow therapeutic index, poor correlation between dose and plasma level, non-availability of an easily measurable clinical endpoint (unlike BP for antihypertensives), and suspected toxicity or non-compliance. * **Drugs NOT requiring TDM:** Drugs with a wide therapeutic index (e.g., Penicillin), or those with easily measurable physiological markers (e.g., Warfarin via PT/INR, Heparin via aPTT, or Antihypertensives via BP). * **Digoxin:** Another classic NTI drug requiring TDM, especially in the presence of hypokalemia which predisposes to toxicity.

Question 378: Alcohol, salicylates, and pilocarpine can be used as:

A. Chelating agents
B. Diaphoretics (Correct Answer)
C. Purging agents
D. Agents for forced alkaline diuresis

Explanation: **Explanation:** **Diaphoretics** are substances that induce or increase sweating (diaphoresis). The correct answer is **B** because alcohol, salicylates, and pilocarpine all possess mechanisms that stimulate sweat production: 1. **Alcohol:** Acts as a peripheral vasodilator. By dilating cutaneous blood vessels, it increases blood flow to the skin, which stimulates sweat glands. 2. **Salicylates (Aspirin):** These act on the hypothalamic thermostat. In febrile states, they reset the "set-point" and promote heat loss through cutaneous vasodilation and profuse sweating. 3. **Pilocarpine:** A direct-acting cholinergic agonist. It stimulates the M3 muscarinic receptors on eccrine sweat glands, making it one of the most potent secretagogues (used clinically in the "Sweat Test" for Cystic Fibrosis). **Analysis of Incorrect Options:** * **A. Chelating agents:** These are used to bind heavy metals (e.g., EDTA, BAL, Penicillamine). None of the listed drugs function as chelators. * **C. Purging agents (Cathartics):** These accelerate defecation (e.g., Magnesium sulfate, Bisacodyl). While pilocarpine increases GI motility, it is not used as a clinical purgative. * **D. Forced alkaline diuresis:** This technique is used to excrete acidic drugs like **salicylates** and phenobarbitone by alkalinizing the urine with Sodium Bicarbonate. While salicylates are *treated* by this method, they do not *cause* it. **NEET-PG High-Yield Pearls:** * **Pilocarpine** is the drug of choice for the **Sweat Chloride Test** to diagnose Cystic Fibrosis. * **Anticholinergics** (like Atropine) cause "anhydrosis" (suppression of sweat), leading to "Atropine fever," especially in children. * **Salicylate poisoning** presents with a mixed respiratory alkalosis and metabolic acidosis; remember that while they induce sweating, the definitive treatment for toxicity is urinary alkalinization.

Question 379: What is the most common drug transport mechanism?

A. Active transport
B. Passive diffusion (Correct Answer)
C. Facilitated diffusion
D. P-glycoprotein

Explanation: **Explanation:** **1. Why Passive Diffusion is Correct:** Passive diffusion is the most common mechanism for drug transport across biological membranes. It occurs along a **concentration gradient** (from higher to lower concentration) and does not require energy (ATP) or carrier proteins. Most drugs are small, lipid-soluble molecules that can easily dissolve in the lipoidal bilayer of the cell membrane. The rate of transport is governed by **Fick’s Law of Diffusion**, where the lipid-water partition coefficient of the drug is the primary determinant. **2. Why Other Options are Incorrect:** * **Active Transport:** This requires energy and specific carrier proteins to move drugs *against* a concentration gradient. While vital for specific substances (e.g., levodopa, iron), it is not the universal mechanism for most drugs. * **Facilitated Diffusion:** This involves a carrier protein but moves drugs *along* a concentration gradient without energy. It is highly specific and saturable, used by molecules like glucose (GLUT transporters), but is less common than simple diffusion. * **P-glycoprotein (P-gp):** This is an efflux transporter (a type of primary active transport) that pumps drugs *out* of cells. It plays a major role in multi-drug resistance and the blood-brain barrier but is a specific transport protein rather than the most common general mechanism. **3. NEET-PG High-Yield Pearls:** * **Lipid Solubility:** The more lipid-soluble (non-ionized) a drug is, the faster it diffuses. * **pH Influence:** Acidic drugs are better absorbed in acidic environments (stomach) because they remain non-ionized. Basic drugs are better absorbed in alkaline environments (intestine). * **Saturability:** Passive diffusion is **non-saturable** and follows first-order kinetics, whereas active and facilitated transport are saturable (follow Michaelis-Menten kinetics). * **Most common site of absorption:** Regardless of the mechanism, the **small intestine** is the primary site for most oral drugs due to its massive surface area.

Question 380: What is the alternative name for a Phase 4 clinical trial?

A. Human pharmacology and safety
B. Post marketing surveillance (Correct Answer)
C. Therapeutic exploration and dose ranging
D. Therapeutic confirmation

Explanation: ### Explanation **Phase 4 Clinical Trials** are conducted after a drug has been granted regulatory approval and is available on the market for the general population. The primary objective is to monitor the drug's performance in real-world scenarios over a long period. **Why "Post Marketing Surveillance" is correct:** Phase 4 is synonymous with **Post Marketing Surveillance (PMS)** because it involves the continuous monitoring of a drug's safety and efficacy in a large, diverse population. Unlike Phases 1-3, which have strict inclusion/exclusion criteria, Phase 4 detects **rare adverse effects**, long-term complications, and drug-drug interactions that may not have surfaced during controlled clinical trials. **Analysis of Incorrect Options:** * **A. Human pharmacology and safety:** This refers to **Phase 1** trials, where the drug is tested for the first time in a small group of healthy volunteers to determine safety, tolerability, and pharmacokinetics. * **C. Therapeutic exploration and dose ranging:** This refers to **Phase 2** trials. These are conducted on a small group of patients to evaluate efficacy and establish the optimum dose range. * **D. Therapeutic confirmation:** This refers to **Phase 3** trials. These are large-scale, multicentric, randomized controlled trials (RCTs) designed to confirm efficacy and safety before seeking marketing approval. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Also known as **Microdosing** studies; uses sub-therapeutic doses to study human pharmacokinetics. * **Phase 4** is the stage where **"Black Box Warnings"** are often added or drugs are **withdrawn** from the market (e.g., Rofecoxib) due to late-emerging toxicity. * **Pharmacovigilance** is the core activity of Phase 4. * **Phase 5:** A newer term sometimes used for translational research or effectiveness studies in the community.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free